Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment. Originating from Dr. Engleman's lab at Stanford University, the company leverages groundbreaking technology to develop tumor-targeted therapies, capitalizing on the combined power of the innate and adaptive immune systems. Backed by top-tier life sciences investors, Bolt is on a promising growth trajectory, dedicated to bringing innovative and curative therapies to patients.
The company’s proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of its therapeutic pipeline, which includes candidates like BDC-1001 and BDC-3042. This platform merges tumor-targeting antibodies with immune-stimulating linker-payloads designed to reprogram the tumor microenvironment, fostering a robust anti-cancer response.
BDC-1001 targets HER2-positive cancers and has shown durable clinical responses and a favorable safety profile in Phase 1 trials. Notably, the FDA granted Orphan Drug Designation to BDC-1001 for gastric cancer treatment, underlining its potential to address unmet medical needs. Phase 2 trials are underway for various cancers, including breast, colorectal, and endometrial cancers.
BDC-3042 targets Dectin-2, a receptor expressed by tumor-associated macrophages (TAMs), and aims to convert these cells from tumor-supportive to tumor-destructive. Having received FDA clearance for its Investigational New Drug (IND) application, BDC-3042 is set to enter Phase 1 trials.
Bolt's pipeline also includes multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies, further validating its platform technology. The company’s financial health is robust, with strategic plans to fund ongoing and future clinical programs.
For more information, visit Bolt Biotherapeutics, Inc. website.
Bolt Biotherapeutics (Nasdaq: BOLT) announced the presentation of comprehensive Phase 1 data for BDC-1001 at the 2023 ASCO Annual Meeting, highlighting its potential as a treatment for HER2-expressing cancers. The Phase 1 trial, which included over 100 patients, demonstrated favorable safety and efficacy results, supporting the recommended Phase 2 dose and schedule. The company plans to initiate two Phase 2 trials in 2023: one evaluating BDC-1001 as a monotherapy for HER2-positive solid tumors and another in combination with nivolumab and pertuzumab. The ASCO presentation will take place on June 3, 2023. BDC-1001 is designed to enhance immune response against tumors via a novel immune-stimulating antibody conjugate mechanism.
Bolt Biotherapeutics announced promising topline data from its Phase 1 clinical study of BDC-1001, validating its Boltbody™ ISAC platform's anti-tumor activity and safety. The company is set to launch a focused Phase 2 program in 2023, exploring BDC-1001 both as a monotherapy and in combination with nivolumab in several cancers, including colorectal, endometrial, and gastroesophageal. Additionally, BDC-3042 is expected to enter the clinic this year. With a strong cash position of $192.8 million, Bolt anticipates funding its key milestones through 2025. Collaboration revenues rose, with significant contributions from Genmab and Innovent.
Bolt Biotherapeutics (Nasdaq: BOLT) announced positive topline data from its Phase 1 dose-escalation study of BDC-1001, a HER2-targeting Immune-Stimulating Antibody Conjugate. Results showed objective clinical responses, including multiple partial responses (PRs) and long-term stable disease across various solid tumor types when administered alone and with nivolumab. The company plans to advance BDC-1001 into Phase 2 studies focusing on breast, colorectal, endometrial, and gastroesophageal cancers. Additionally, a collaboration with Roche will supply pertuzumab (Perjeta®) for further investigations, highlighting the ongoing commitment to developing innovative cancer therapies.
Bolt Biotherapeutics (Nasdaq: BOLT) announced plans to present new preclinical data for BDC-3042, an agonistic antibody targeting Dectin-2, at the AACR Annual Meeting 2023 from April 14-19. The data highlights BDC-3042's mechanism of action in reprogramming tumor-associated macrophages (TAMs) to enhance anti-tumor immunity. Key findings include strong binding to TAMs, pro-inflammatory cytokine production, and tumor growth inhibition in humanized mouse models. Bolt aims to move BDC-3042 into clinical trials this year, emphasizing its potential across various cancers. The presentation details will be available post-conference on Bolt’s website.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on
immuno-oncology therapeutics for cancer treatment, announced its management will present at the
Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 2:50 p.m. EST in Boston, Mass. A live webcast
of the presentation will be accessible on Bolt's website, with archived replays available for 30 days.
The company is advancing its drug pipeline, including BDC-1001 for HER2-expressing tumors and BDC-3042, targeting Dectin-2.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, announced its participation in two key conferences in February 2023. Management will engage in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Day on February 8 at 12:55 p.m. PST, followed by another chat at the Virtual SVB Securities Global Biopharma Conference 2023 on February 16 at 12:40 p.m. PST. Live webcasts of these events will be available on Bolt's website, with archived replays accessible for 30 days post-event. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on its pipeline candidates, including BDC-1001 and BDC-3042.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has appointed Laura Berner to its Board of Directors as of December 14, 2022. Laura brings extensive experience in biopharmaceuticals, having executed over 50 transactions in her career. Her strategic insights are expected to support Bolt's ongoing development of its immunotherapy pipeline, particularly BDC-1001, which is advancing into Phase 2 clinical trials, and BDC-3042, slated for clinical evaluation. CEO Randall Schatzman expressed enthusiasm for her contributions, highlighting her potential to enhance Bolt's commitment to cancer treatment.
FAQ
What is the current stock price of Bolt Biotherapeutics (BOLT)?
What is the market cap of Bolt Biotherapeutics (BOLT)?
What is Bolt Biotherapeutics, Inc.?
What is the Boltbody™ ISAC platform?
What are BDC-1001 and BDC-3042?
What recent achievements has Bolt Biotherapeutics made?
Who backs Bolt Biotherapeutics?
What is the significance of Orphan Drug Designation for BDC-1001?
What are the goals of the BDC-3042 program?
What partnerships does Bolt Biotherapeutics have?
How is Bolt Biotherapeutics advancing its clinical programs?
Where can I find more information about Bolt Biotherapeutics?
